本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Prelude Therapeutics Inc

3.50
+0.07502.19%
成交量:4,137.00
成交額:1.45萬
市值:2.20億
市盈率:-2.70
高:3.58
開:3.45
低:3.45
收:3.42
52周最高:4.22
52周最低:0.6101
股本:6,286.53萬
流通股本:250.24萬
量比:2.46
換手率:0.17%
股息:- -
股息率:- -
每股收益(TTM):-1.2929
每股收益(LYR):-1.2929
淨資產收益率:-99.45%
總資產收益率:-40.74%
市淨率:3.20
市盈率(LYR):-2.70

資料載入中...

2021/03/08

重要事件披露

8-K - Current report
2021/02/11

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/02/10

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/02/08

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/01/29

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/01/28

重要事件披露

8-K - Current report
2021/01/14

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/01/04

SEC問詢函

CORRESP [Cover] - Correspondence
2021/01/04

SEC問詢函

CORRESP [Cover] - Correspondence
2021/01/04

重要事件披露

8-K - Current report
2021/01/04

招股説明書

S-1 - General form for registration of securities under the Securities Act of 1933
2020/11/10

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2020/11/10

重要事件披露

8-K - Current report
2020/11/04

重要事件披露

8-K - Current report
2020/10/05

超過5%披露

SC 13D - General statement of acquisition of beneficial ownership
2020/09/30

超過5%披露

SC 13D - General statement of acquisition of beneficial ownership
2020/09/25

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2020/09/22

SEC問詢函

CORRESP [Cover] - Correspondence
2020/09/22

SEC問詢函

CORRESP [Cover] - Correspondence
2020/09/21

[修訂]招股説明書

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933